Biodistribution of 211At-labeled humanized monoclonal antibody A33

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 4, 2007, Pages 480-487

  Almqvist, Ylva ^a,c   Steffen, Ann Charlott ^a   Lundqvist, Hans ^a   Jensen, Holger ^b   Tolmachev, Vladimir ^a   Sundin, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Rigshospitalet   (Denmark)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

211At; A33; Biodistribution; Monoclonal antibody; Radioimmunotherapy

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A33; RADIOISOTOPE; UNCLASSIFIED DRUG; ASTATINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG SCREENING; FEMALE; GENE TARGETING; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; POSITRON; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE DISTRIBUTION; TUMOR; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; HUMAN; IMMUNOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85047695337     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.349A     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153.
2. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004;40:1292.
3. Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353:391.
4. Ohlsson B, Pålsson B. Follow-up after colorectal cancer surgery. Acta Oncol 2003;42:816.
5. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818.
6. 131I- counter-part. Cancer Lett 2005;219:41.
7. Behr TM, Behe M, Lohr M, et al. Therapeutic advantages of Auger electron-over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000;27:753.
8. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res 1997;57:447.
9. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: The coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001;39:195.
10. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52:281.
11. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814S.
12. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002;94:1373.
13. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693.
14. Vaidyanathan G, Zalutsky MR. Targeted therapy using alpha-emitters. Phys Med Biol 1996;41:1915.
15. 211At-labeled antibody A33 - a potential therapeutic agent against metastatic colorectal carcinoma. Cancer Biother Radiopharm 2005;20:514.
16. Koziorowski J, Henssen C, Weinreich R. A new convenient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for radioiodination of proteins. Appl Radiat Isotopes 1998;49:955.
17. Hoglund J, Tolmachev V, Orlova A, et al. Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET. Nucl Med Biol 2000;27:837.
18. 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 2005;11:4818.
19. Sakamoto J, Oriuchi N, Mochiki E, et al. A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma. Cancer Sci 2006;97:1248.
20. Scott AM, Lee FT, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005;11:4810.
21. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233.
22. 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem Rev 2001;101:2019.
23. Couturier O, Supiot S, Degraef-Mougin M, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 2005;32:601.
24. Zalutsky MR, Zhao XG, Alston KL, et al. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. J Nucl Med 2001;42:1508.
25. Zalutsky MR. Current status of therapy of solid tumors: Brain tumor therapy. J Nucl Med 2005;46(Suppl 1):151S.
26. Garin-Chesa P, Sakamoto J, Welt S, et al. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol 1996;9:465.
27. Nestor M, Persson M, Cheng J, et al. Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker: Comparison with other radioiodination methods. Bioconjug Chem 2003;14:805.
28. 211At in a murine intraperitoneal tumor model. Gynecol Oncol 1995;57:9.
29. Zalutsky MR, Stabin MG, Larsen RH, et al. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Nucl Med Biol 1997;24:255.
30. Orlova A, Höglund J, Lubberink M, et al. Comparative biodistribution of the radiohalogenated (Br, I, and At) antibody A33: Implications for in vivo dosimetry. Cancer Biother Radiopharm 2002;17:385.
31. 211At- EGF. Eur J Nucl Med Mol Imaging 2003;30:1348.
32. Persson MI, Gedda L, Jensen HJ, et al. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol Rep 2006;15:673.